Home
HRTX
HRTX News

Latest Heron Therapeutics Inc. (HRTX) News on October 20, 2025

MT Newswires

4 months ago

HC Wainwright Initiates Coverage on Heron Therapeutics With Buy Rating, $6 Price Target

Ulta Stock Jumps as Beauty Product Spending Continues

Investopedia

5 months ago

Ulta Stock Jumps as Beauty Product Spending Continues

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

GlobeNewswire

5 months ago

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

GlobeNewswire

5 months ago

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

Northrop Grumman Raises $1 Billion Via Debt

Benzinga

5 months ago

Northrop Grumman Raises $1 Billion Via Debt

The York Water Company Files a Rate Request Based on $145 Million in Investment

GlobeNewswire

5 months ago

The York Water Company Files a Rate Request Based on $145 Million in Investment

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

GlobeNewswire

5 months ago

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

Newsfile

5 months ago

Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

GlobeNewswire

5 months ago

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

Results: Heron Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Simply Wall St.

5 months ago

Results: Heron Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Heron Therapeutics First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Heron Therapeutics First Quarter 2025 Earnings: Beats Expectations

GuruFocus.com

5 months ago

Heron Therapeutics Inc (HRTX) Q1 2025 Earnings Call Highlights: Record EBITDA and Significant ...

MT Newswires

5 months ago

Heron Settles Patent Litigation With Mylan Over Cinvanti, Aponvie; Shares Rise

Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics

Zacks

5 months ago

Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics

Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates

Zacks

5 months ago

Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates

Associated Press Finance

5 months ago

Heron Therapeutics: Q1 Earnings Snapshot

Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

PR Newswire

5 months ago

Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

PR Newswire

5 months ago

Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

6 months ago

Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?

Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zacks

6 months ago

Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

MT Newswires

6 months ago

Heron Therapeutics Names Mark Hensley as COO

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

PR Newswire

6 months ago

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

Zacks

6 months ago

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Zacks

6 months ago

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Zacks

6 months ago

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

PR Newswire

6 months ago

Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

Best Momentum Stocks to Buy for April 22nd

Zacks

6 months ago

Best Momentum Stocks to Buy for April 22nd

Are Medical Stocks Lagging Encompass Health (EHC) This Year?

Zacks

6 months ago

Are Medical Stocks Lagging Encompass Health (EHC) This Year?

Exploring High Growth Tech Stocks In The US Market April 2025

Simply Wall St.

7 months ago

Exploring High Growth Tech Stocks In The US Market April 2025

Loss-Making Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected To Breakeven In The Medium-Term

Simply Wall St.

7 months ago

Loss-Making Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected To Breakeven In The Medium-Term

Is Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5?

Insider Monkey

7 months ago

Is Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5?

Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported Earnings, And Analysts Cut Their Target Price

Simply Wall St.

8 months ago

Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported Earnings, And Analysts Cut Their Target Price

High Growth Tech Stocks to Watch in US Market February 2025

Simply Wall St.

8 months ago

High Growth Tech Stocks to Watch in US Market February 2025

Heron Therapeutics (NASDAQ:HRTX) shareholders are up 19% this past week, but still in the red over the last five years

Simply Wall St.

8 months ago

Heron Therapeutics (NASDAQ:HRTX) shareholders are up 19% this past week, but still in the red over the last five years

Heron Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

8 months ago

Heron Therapeutics Full Year 2024 Earnings: Beats Expectations

GuruFocus.com

8 months ago

Heron Therapeutics Inc (HRTX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Heron Therapeutics Inc Earnings Call

Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

8 months ago

Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Associated Press Finance

8 months ago

Heron Therapeutics: Q4 Earnings Snapshot

Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

PR Newswire

8 months ago

Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025

PR Newswire

8 months ago

Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025

Heron Therapeutics, Inc. (NASDAQ:HRTX) is a favorite amongst institutional investors who own 58%

Simply Wall St.

9 months ago

Heron Therapeutics, Inc. (NASDAQ:HRTX) is a favorite amongst institutional investors who own 58%

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

PR Newswire

10 months ago

Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

10 months ago

Exploring Three High Growth Tech Stocks In The United States

MT Newswires

a year ago

Top Premarket Gainers

MT Newswires

a year ago

Update: Heron Therapeutics Shares Surge Premarket Following Favorable Cinvanti Patent Ruling

MT Newswires

a year ago

Heron Therapeutics Shares Surge on Favorable Cinvanti Patent Ruling

U.S. District Court Upholds Validity of CINVANTI® Patents

PR Newswire

a year ago

U.S. District Court Upholds Validity of CINVANTI® Patents

GuruFocus.com

a year ago

Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ...

Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks

a year ago

Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Zacks

a year ago

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Associated Press Finance

a year ago

Heron Therapeutics: Q3 Earnings Snapshot

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

PR Newswire

a year ago

Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics

Zacks

a year ago

Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics

Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock

Simply Wall St.

a year ago

Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

PR Newswire

a year ago

Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?

Zacks

a year ago

Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

PR Newswire

a year ago

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

MT Newswires

a year ago

Heron Therapeutics Reaffirms Supply of Ready-to-Administer Nausea Prevention Medications

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

PR Newswire

a year ago

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability

Simply Wall St.

a year ago

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability

MT Newswires

a year ago

Heron Therapeutics Receives FDA Approval for Zynrelef Extended-Release Solution

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

PR Newswire

a year ago

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

a year ago

Exploring Three High Growth Tech Stocks in the United States

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

PR Newswire

a year ago

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

Heron Therapeutics Second Quarter 2024 Earnings: EPS Misses Expectations

Simply Wall St.

a year ago

Heron Therapeutics Second Quarter 2024 Earnings: EPS Misses Expectations

Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

a year ago

Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Zacks

a year ago

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Associated Press Finance

a year ago

Heron Therapeutics: Q2 Earnings Snapshot

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

PR Newswire

a year ago

Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

PR Newswire

a year ago

Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024

While shareholders of Heron Therapeutics (NASDAQ:HRTX) are in the black over 1 year, those who bought a week ago aren't so fortunate

Simply Wall St.

a year ago

While shareholders of Heron Therapeutics (NASDAQ:HRTX) are in the black over 1 year, those who bought a week ago aren't so fortunate

MT Newswires

a year ago

Heron Therapeutics Says Non-Opioid Pain Medication to be Included in Proposed Medicare Programs

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

PR Newswire

a year ago

Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know

Zacks

a year ago

Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

Zacks

a year ago

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

MT Newswires

a year ago

Heron Reports Acceptance of Prior Approval Supplement Application for Zynrelef Vial Access Needle

Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

Zacks

a year ago

Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

PR Newswire

a year ago

Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

With 55% ownership of the shares, Heron Therapeutics, Inc. (NASDAQ:HRTX) is heavily dominated by institutional owners

Simply Wall St.

a year ago

With 55% ownership of the shares, Heron Therapeutics, Inc. (NASDAQ:HRTX) is heavily dominated by institutional owners

Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?

Zacks

a year ago

Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

Zacks

a year ago

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

Zacks

a year ago

FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

MT Newswires

a year ago

Connect Biopharma Names New Chief Executive, Chair

Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug

Zacks

a year ago

Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

Yahoo Finance Video

a year ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

GlobeNewswire

a year ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

Reuters

a year ago

California seeks company profits in Big Oil climate lawsuit

USA TODAY

a year ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Business Wire

a year ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

GlobeNewswire

a year ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

GlobeNewswire

a year ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

a year ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease

Zacks

a year ago

Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease

Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO

Zacks

a year ago

Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

Zacks

a year ago

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms

Zacks

a year ago

J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms

Merck (MRK) to Buy Private Ophthalmology Company EyeBio

Zacks

a year ago

Merck (MRK) to Buy Private Ophthalmology Company EyeBio

Pleasing Signs As A Number Of Insiders Buy Heron Therapeutics Stock

Simply Wall St.

a year ago

Pleasing Signs As A Number Of Insiders Buy Heron Therapeutics Stock

Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

Zacks

a year ago

Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

Share on Social Networks: